Juliet Keidan Institute of Pediatric Gastroenterology Hepatology and Nutrition, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem.
Maccabi Health Services, Tel Aviv, Israel and the Sackler Faculty of Medicine, Tel Aviv University.
J Pediatr Gastroenterol Nutr. 2022 Jun 1;74(6):788-793. doi: 10.1097/MPG.0000000000003422. Epub 2022 Feb 22.
Both perianal and pediatric-onset Crohn disease (CD) disease are associated with complicated disease course and higher drug utilization. we aimed to explore the differences between pediatric and adult-onset perianal CD and their disease course.
We included all patients with newly diagnosed CD from 2005 to 2019 at two Israeli Health Maintenance Organizations, covering 78% of the population. A combination of ICD-9 codes, radiology and procedures was used to define fistulizing perianal CD (PCD) and its severity according to the association with simple and complex perianal disease.
A total of 12,905 patients were included (2186 [17%] pediatric-onset, 10,719 [83%] adults), with a median follow-up of 7.8 years. PCD was diagnosed in 1530 (12%) patients, with higher incidence in children (308 [14%] children vs 1222 adults [11%]; P < 0.001). Children had higher incidence of severe PCD (141/308 [47%] vs 433/1222 [35%]; P < 0.001). At 5 years, children with PCD were more likely than adults to be treated with biologics (212 [69%] vs 515 [42%]; odds ratio [OR] 2.6 [95% confidence interval (CI) 1.6-4.0]; P < 0.001) and immunomodulators (238 [74%] vs 643 [53%]; OR 2.8 [95% CI 2.1-3.6]; P < 0.001). PCD in children was still associated with poorer disease outcomes as shown for surgeries (36 [12%] vs 93 [8%]; P = 0.02) and steroid-dependency (52 [17%] vs 156 [13%]; P < 0.001). Multivariable modeling indicated that the severity of PCD is a stronger predictor of disease course than age.
PCD is more common in pediatric-onset CD and is associated with higher drug utilization and worse disease outcomes, in large due to higher rate of severe PCD in children.
肛周和儿科发病的克罗恩病(CD)都与复杂的疾病过程和更高的药物利用相关。我们旨在探讨儿科和成人发病肛周 CD 之间的差异及其疾病过程。
我们纳入了 2005 年至 2019 年在两个以色列健康维护组织新诊断的所有 CD 患者,涵盖了 78%的人群。使用 ICD-9 编码、影像学和操作相结合的方法,根据与简单和复杂肛周疾病的关联,定义瘘管性肛周 CD(PCD)及其严重程度。
共纳入 12905 例患者(2186 例[17%]儿科发病,10719 例[83%]成人),中位随访时间为 7.8 年。1530 例(12%)患者诊断为 PCD,儿童中发生率更高(308 例[14%]儿童 vs 1222 例成人[11%];P<0.001)。儿童中严重 PCD 的发生率更高(141/308 [47%] vs 433/1222 [35%];P<0.001)。在 5 年时,与成人相比,患有 PCD 的儿童更有可能接受生物制剂治疗(212 例[69%] vs 515 例[42%];比值比[OR] 2.6 [95%置信区间(CI)1.6-4.0];P<0.001)和免疫调节剂(238 例[74%] vs 643 例[53%];OR 2.8 [95% CI 2.1-3.6];P<0.001)。儿童中 PCD 与手术(36 例[12%] vs 93 例[8%];P=0.02)和激素依赖性(52 例[17%] vs 156 例[13%];P<0.001)较差的疾病结局仍相关。多变量建模表明,PCD 的严重程度是疾病过程的更强预测因素,而非年龄。
在儿科发病的 CD 中,PCD 更为常见,且与更高的药物利用和更差的疾病结局相关,这主要是由于儿童中严重 PCD 的发生率更高。